FOLH1 and prostate carcinoma: The rapidly evolving field of theragnostics includes some already approved treatments such as 177Lu-PSMA (prostate-specific membrane antigen) for prostate cancer, 223Ra for osseous metastases, 177Lu-DOTATATE for neuroendocrine tumors, 131I for thyroid cancer, and several others that are under development [3].